期刊文献+

硼中子俘获治疗对裸鼠脏器影响的实验研究 被引量:1

The effect of boron neutron capture therapy on internal organs of nude mice
暂未订购
导出
摘要 目的采用动物实验方法研究硼中子俘获疗法(BNCT)对于正常脏器的损伤作用,从而为其安全性研究提供依据。方法实验动物裸小鼠随机分成单纯照射中子组(Ⅰ组),单纯给药组(Ⅱ组),BNCT 1、2、3组(Ⅲ、Ⅳ、Ⅴ组)。其中BNCT 1组为注射硼携带剂BPA(300 mg/kg,B.W.)2.5 h后接受超热中子束满功率照射10 min,BNCT 2组为注射硼携带剂BPA(500 mg/kg,B.W.)2.5 h后接受超热中子束满功率照射10 min,BNCT 3组为注射硼携带剂BPA(300 mg/kg,B.W.)2.5 h后接受超热中子束满功率照射15 min。实验完成后2周处理动物,将各组动物脏器心、肺、肝、脾、肾、膀胱切取后HE染色,病理切片,两名经验丰富的病理科医师观察脏器淤血,水肿,坏死,增生情况。结果将各组数据统计学处理采用等级计数资料的Ridit分析。结果显示各组心、肺、脾、肾、膀胱损伤及肝细胞坏死及非典型增生差异无统计学意义,肝组织淤血、水样变性实验组损伤小于对照组,差异有统计学意义。结论 BNCT对裸鼠脏器损伤小,是一项安全的治疗方法,为进一步用BNCT治疗肿瘤提供了依据。 Objective The effect of boron neutron capture therapy(BNCT) on normal organs was examined in nude mice.Methords Thirty mice were randomly allocated into five groups: control group without BPA(group I),control group without radiation(group II),BNCT-1,BNCT-2 and BNCT-3(Ⅲ,Ⅳ and Ⅴ) groups.The histological examination of internal organs including heart,lung,liver,spleen,kidney and bladder were taken two weeks later.Results The results indicated that BNCT did not increase the possibility of necrosis and atypical hyperplasia in internal organs including heart,lung,liver,spleen,kidney and bladder in comparison with those of control group,and the occurrence of congestion and hydropic degeneration in liver tissues was less than those of control group.Conclusion The BNCT protocols indicated that BNCT at selected dosage does not impair the normal function of internal organs.
出处 《临床和实验医学杂志》 2012年第9期644-647,共4页 Journal of Clinical and Experimental Medicine
关键词 硼中子俘获治疗 裸鼠 脏器 Boron neutron capture therapy Nude mice Internal organs
  • 相关文献

参考文献7

二级参考文献48

  • 1罗全勇,朱瑞森.硼中子俘获治疗[J].同位素,2004,17(3):174-177. 被引量:14
  • 2YANG W, BARTH RF, WU G, et al. Molecular targeting and treatment of EGFRvlII-positive gliomas using boronated monoclonal antibody L8A4 [ J]. Clin Cancer Res, 2006, 12 (12) : 3792 - 3802.
  • 3WU G, BARTH RF, YANG W, et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab(IMC-C225)and its evaluation as a potential delivery agent for neutron capture therapy[ J]. Bioconjug Chem, 2004, 15(1) :185 - 194.
  • 4BARTH RF, WU G, YANG W, et al. Neutron capture therapy of epidermal growth factor ( + ) gliomas using boronated cetuximab( IMC-C225 ) as a delivery agent [ J]. Appl Radiat Isot,2004, 61(5): 899 -903.
  • 5YANG W, BARTH RF, ADAMS DM, et al. Intratumoral delivery of boronated epidermal growth factor for capture therapy of brain tumors[J]. Cancer Res, 1997, 57(19) :4333 -4339.
  • 6GEDDA L, OLSSON P, PONTEN J, et al. Development and in vitro studies of epidermal growth factor-dextran conjugates fur boron neutron capture therapy[ J]. Bioconjug Chem, 1996, 7 (5) : 584 - 591.
  • 7GOODMAN JH,YANG W,BARTH RF,et al. Boron neutron capture therapy of brain tumors: biodistribution, pharmacokinetics, and radiation dosimetry sodium borocaptate in patients with gliomas [ J ]. Neurosurgery, 2000, 47 (3) : 608 - 621, discussion 21 - 22.
  • 8BEDDOE AH. Boron neutron capture therapy[ J]. Br J Radiol, 1997, 70(835) :665 -621.
  • 9FEINENDEGEN LE. Strategic planning workshop on research needs for neutron capture therapy [ J ]. J Neurooncol, 1997, 33 ( 1 - 2) : 179 - 185.
  • 10周永茂.硼中子俘获疗法争议中的五对问题.清华大学学报:自然科学版,2000,40(3):128-137.

共引文献10

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部